Abstract 231P
Background
Our research is focused on vitamin D3 active form calcitriol and its analog tacalcitol, and their interactions on the immune system, including Th17 lymphocytes, which plays a significant role in the development and progression of breast cancer. The aim was to analyze the direct effect of vitamin D compounds on its nuclear receptors in Th17 cells and changes in IL-17 production. The interaction with osteopontin (OPN) was examined as the example of indirect influence on Th17 cells population in breast cancer. Taking into account the hormonal status during disease development and stimulation of the immune system, we used mice: 6-8 weeks old as a premenopausal and 35-40 weeks old, ovariectomized, as a postmenopausal model. Our research was mainly focused on CD4+ lymphocytes isolated from spleens, looking forward to Th17 helper lymphocytes differentiation after treatment.
Methods
Animals bearing EMT6 or E0771 murine mammary gland cancer tumours were administered with calcitriol or tacalcitol from day 7 after inoculation, every three days, in the dose of 0.5 μg/kg or 1 μg/kg body weight/day, respectively. Local Ethics Committee permission No 50/2020. CD4+ cells (splenocytes) were isolated, cultured and examined for subpopulation phenotype, differentiation into Th17, gene expression profile, OPN impact on Th17 differentiation, expression of OPN receptors.
Results
Both compounds inhibited E0771 tumor growth, but tacalcitol increased metastasis in aged mice. The growth of EMT-6 tumors was stimulated in young and inhibited in aged mice after tacalcitol treatment. Metastasis was inhibited independently of the age by tacalcitol. In the E0771 premenopausal and EMT6 postmenopausal groups, tacalcitol increased the number of gene transcripts for IL17. The same tendency was observed in the E0771 postmenopausal group for the Il17 and Rorc genes. Blocking of selected CD4+ surface receptors (CD44, CD51), related to OPN functions, resulted in an increase of iTh17 cells after tacalcitol treatment. Tacalcitol in iTh17 cells induced the mRNA level for VDR, OPN, IL-21 and IL17R coding genes.
Conclusions
The Th17 induction via the OPN plays an important role, especially after tacalcitol treatment. Both compounds affect Th17 lymphocytes depending on the tumor type and age of mice.
Legal entity responsible for the study
The authors.
Funding
The National Science Center, OPUS 18 grant No. 2019/35/B/NZ5/01250.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session